^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

PD64-01: The status of the tumor suppressors VHL and CDKN2A impacts clear cell renal cell carcinoma sensitivity to CDK 4/6 inhibitors

Published date:
05/15/2020
Excerpt:
The FDA-approved CDK4/6 inhibitor palbociclib showed an effective response in ccRCC with wild-type VHL and mutated CDKN2A